Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real-world treatment patterns, outcomes, and healthcare resource utilization in relapsed or refractory multiple myeloma: evidence from a medical record review in France. Adv Hematol. 2019 Jan 29;2019(4625787). doi: 10.1155/2019/4625787
Song W, Musetti SN, Huang L. Nanomaterials for cancer immunotherapy. Biomaterials. 2017 Dec;148:16-30. doi: 10.1016/j.biomaterials
Luo C, Miao L, Zhao Y, Musetti S, Wang Y, Shi K, Huang L. A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. Biomaterials. 2016 Sep;102:239-48. doi: 10.1016/j.biomaterials.2016.06.030
Davis KL, Cote I, Kaye JA, Mendelson E, Gao H, Perez Ronco J. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015 Oct;2015(2015):848473. doi: 10.1155/2015/848473
Hirsch IB, Xu Y, Davis KL, Calingaert B. Patient factors associated with glucagonlike peptide 1 receptor agonist use with and without insulin. Endocr Pract. 2011 Sep 1;17(5):707-16.
Tunceli K, Pladevall-Vila M, Williams LK, Divine GW, Simpkins JC, Nag SS, Sajjan SG, Kamal-Bahl SJ, Alexander CM, Lafata JE. Trends in lipid management among patients with diabetes. Endocr Pract. 2006 Jul;12(4):380-7.
Chen XH, Rodríguez S, Hawe E, Talmud PJ, Miller GJ, Underhill P, Humphries SE, Day IN. Evidence of admixture from haplotyping in an epidemiological study of UK Caucasian males: implications for association analyses. Hum Hered. 2004;57(3):142-55.
Andrews CW, Bennett L, Yu LX. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm Res. 2000 Jun 1;17(6):639-44.